Pliant touches record low after scrapping trial of lung-disease drug

Pliant Therapeutics

03/03/2025 15:45

** Shares of drug developer Pliant Therapeutics PLRX.O hit their lowest level on record at $1.59

  ** The company discontinues a mid-stage trial of its experimental drug bexotegrast in patients with a type of lung disease called idiopathic pulmonary fibrosis

  ** PLRX says the drug trial was stopped due to reports of IPF-related adverse events

  ** Idiopathic pulmonary fibrosis is a chronic lung disease that causes scarring and stiffening of the organ's tissue

  ** PLRX paused enrollment of patients in the mid-stage trial in early February, on the recommendation of an independent data safety monitoring board

  ** It plans to analyze complete trial data and evaluate next steps for bexotegrast's development, including additional studies testing lower doses in IPF

  ** The stock is down 79.3% in the past 12 months

 (Reporting by Padmanabhan Ananthan)

 ((Padmanabhan.Ananthan@thomsonreuters.com;))